Heino Prondzynski - Epigenomics AG Insider

EPGNF -- USA Stock  

USD 2.68  0.0029  0.11%

Mr. Heino von Prondzynski is Chairman of the Supervisory Board of Epigenomics AG since May 2, 2012. He was Member of the Supervisory Board at Epigenomics AG from May 29, 2007 until March 31, 2010. Until December 2005, he headed the Diagnostics Division at F.HoffmannLa Roche AG, Basel. Before that, he held senior positions in the Vaccine business at Chiron Corporationration in Germany, Italy and the Unted States and in the Pharma, Selfmedication and Diagnostic business at Bayer AG in Germany, Austria and Brazil. After retiring from his position as Chief Executive Officer of the Roche Diagnostics division, Mr. von Prondzynski works as Independent Consultant. He serves at the Supervisory Boards of Koninklijke Philips Electronics NV, Qiagen NV and Hospira Inc., among others.
Age: 67  Chairman Since 2012      
49 30 243 450  http://www.epigenomics.com
von Prondzynski studied mathematics, geography, and history at the Westfaelische WilhelmsUniversitaet, Muenster, Germany.

Management Efficiency

The company has return on total asset (ROA) of (44.29) % which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (122.69) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.

Similar Executives

Entity Summary

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics AG is traded on OTC Market in USA.Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Geneststrasse 5 and employs 43 people.

Epigenomics AG Leadership Team

Antje Zeise, Manager Investor Relations
Guenther Reiter, Member of the Supervisory Board
Gregory Hamilton, CEO
Ann Kessler, Member of the Supervisory Board
Heino Prondzynski, Chairman of the Supervisory Board
Helge Lubenow, Member of the Supervisory Board
Thomas Taapken, CEO, CFO and Member of Executive Board
Annett Dietrich, Manager Human Resources
Noel Doheny, CEO of Epigenomics Inc.
Uwe Staub, COO and Member of Executive Board
Albert Weber, Sr. VP of Fin., Accounting and Controlling
Nicola HennebergBusse, Vice President - Business Development
Jorge Garces, President Chief Scientific Officer
Nicholas Potter, Director Reimbursement and Medical Affairs
Peter Vogt, Investor & Public Relations Officer

Stock Performance Indicators

Current Sentiment - EPGNF

Epigenomics AG Investor Sentiment
Macroaxis portfolio users are insensible in their opinion about investing in Epigenomics AG. What is your opinion about investing in Epigenomics AG? Are you bullish or bearish?
50% Bullish
50% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Epigenomics AG and Apple. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.